Deep-pocketed investors have adopted a bullish approach towards Novo Nordisk (NYSE:NVO), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NVO usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 22 extraordinary options activities for Novo Nordisk. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 31% bearish. Among these notable options, 9 are puts, totaling $571,820, and 13 are calls, amounting to $1,045,859.
Projected Price Targets
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $45.0 to $170.0 for Novo Nordisk over the recent three months.
Insights into Volume & Open Interest
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Novo Nordisk's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Novo Nordisk's whale trades within a strike price range from $45.0 to $170.0 in the last 30 days.
Novo Nordisk Call and Put Volume: 30-Day Overview
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|
| NVO | CALL | TRADE | BEARISH | 02/21/25 | $2.0 | $1.93 | $1.94 | $95.00 | $397.7K | 1.1K | 2.1K |
| NVO | CALL | SWEEP | BULLISH | 01/16/26 | $13.1 | $13.05 | $13.1 | $87.50 | $217.4K | 69 | 205 |
| NVO | PUT | SWEEP | BULLISH | 02/21/25 | $34.75 | $33.1 | $33.6 | $120.00 | $165.8K | 0 | 50 |
| NVO | CALL | SWEEP | BEARISH | 01/17/25 | $5.1 | $4.95 | $4.96 | $82.50 | $99.2K | 1.1K | 201 |
| NVO | PUT | TRADE | BULLISH | 01/16/26 | $85.2 | $83.65 | $83.68 | $170.00 | $83.6K | 10 | 10 |
About Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
After a thorough review of the options trading surrounding Novo Nordisk, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Novo Nordisk's Current Market Status
- With a volume of 3,808,605, the price of NVO is down -1.21% at $86.31.
- RSI indicators hint that the underlying stock may be oversold.
- Next earnings are expected to be released in 37 days.
What The Experts Say On Novo Nordisk
1 market experts have recently issued ratings for this stock, with a consensus target price of $105.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access.* An analyst from BMO Capital has decided to maintain their Outperform rating on Novo Nordisk, which currently sits at a price target of $105.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
財力雄厚的投資者對諾和諾德（紐約證券交易所代碼：NVO）採取了看漲態度，這是市場參與者不容忽視的。我們對本辛加公開期權記錄的追蹤今天揭示了這一重大舉措。這些投資者的身份仍然未知，但是NVO的如此實質性的變動通常表明重大事件即將發生。
我們今天從觀察中收集了這些信息，當時Benzinga的期權掃描儀重點介紹了諾和諾德的22項非同尋常的期權活動。這種活動水平與衆不同。
這些重量級投資者的總體情緒存在分歧，50％的人傾向於看漲，31％的人看跌。在這些值得注意的期權中，有9個是看跌期權，總額爲571,820美元，13個是看漲期權，總額爲1,045,859美元。
預計的目標價格
根據交易活動，看來重要投資者的目標是在最近三個月中將Novo Nordisk的價格範圍從45.0美元擴大到170.0美元。
對交易量和未平倉合約的見解
交易期權時，查看交易量和未平倉合約是一個強有力的舉動。這些數據可以幫助您跟蹤Novo Nordisk期權在給定行使價下的流動性和利息。下面，我們可以觀察過去30天內諾和諾德所有鯨魚交易的看漲和看跌期權交易量和未平倉合約的變化，其行使價在45.0美元至170.0美元之間。
Novo Nordisk 看漲和看跌交易量：30 天概述
檢測到的重大期權交易：
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|
NVO | CALL | TRADE | BEARISH | 02/21/25 | $2.0 | $1.93 | $1.94 | $95.00 | $397.7K | 1.1K | 2.1K |
NVO | CALL | SWEEP | BULLISH | 01/16/26 | $13.1 | $13.05 | $13.1 | $87.50 | $217.4K | 69 | 205 |
NVO | PUT | SWEEP | BULLISH | 02/21/25 | $34.75 | $33.1 | $33.6 | $120.00 | $165.8K | 0 | 50 |
NVO | CALL | SWEEP | BEARISH | 01/17/25 | $5.1 | $4.95 | $4.96 | $82.50 | $99.2K | 1.1K | 201 |
NVO | PUT | TRADE | BULLISH | 01/16/26 | $85.2 | $83.65 | $83.68 | $170.00 | $83.6K | | |
關於諾和諾德
Novo Nordisk擁有全球品牌糖尿病治療市場約三分之一的份額，是全球領先的糖尿病護理產品提供商。該公司總部位於丹麥，生產和銷售各種人類和現代胰島素、可注射的糖尿病治療藥物，例如 GLP-1 療法、口服抗糖尿病藥物和肥胖療法。Novo還有一個生物製藥板塊（約佔收入的10％），專門從事血友病和其他疾病的蛋白質療法。
在對圍繞Novo Nordisk的期權交易進行了全面審查之後，我們將對該公司進行更詳細的審查。這包括評估其當前的市場狀況和表現。
諾和諾德的當前市場狀況
專家對諾和諾德的看法
1位市場專家最近發佈了該股的評級，共識目標價爲105.0美元。
檢測到不尋常的期權活動：智能貨幣在移動
Benzinga Edge的不尋常期權委員會在潛在的市場推動者發生之前就發現了它們。看看大筆資金對你最喜歡的股票持有哪些頭寸。點擊此處查看。* BMO Capital的一位分析師已決定維持對Novo Nordisk的跑贏大盤評級，該評級目前的目標股價爲105美元。
與僅交易股票相比，期權是一種風險更高的資產，但它們具有更高的盈利潛力。嚴肅的期權交易者通過每天進行自我教育、擴大交易規模、遵循多個指標以及密切關注市場來管理這種風險。
